BC Innovations | Aug 16, 2018
Distillery Therapeutics


INDICATION: Autism Mouse studies suggest optogenetically activating or agonizing 5-HT1B receptors on neurons projecting from the dorsal raphe to the nucleus accumbens could help treat autism spectrum disorders (ASDs) caused by a deletion at the...
BC Week In Review | Sep 12, 2016
Company News

RetroSense Therapeutics, Allergan deal

Allergan acquired RetroSense for $60 million in cash up front and undisclosed regulatory and commercialization milestones. Allergan gained retinitis pigmentosa (RP) candidate RST-001 , an adeno-associated virus (AAV) 2 vector activating the channelrhodopsin-2 (ChR2) gene. In...
BC Extra | Sep 6, 2016
Company News

Allergan buys gene therapy play RetroSense

Allergan plc (NYSE:AGN) acquired RetroSense Therapeutics LLC (Ann Arbor, Mich.), giving it retinitis pigmentosa (RP) candidate RST-001 . RetroSense shareholders received $60 million up front and are eligible for undisclosed regulatory and commercialization milestones. Allergan declined...
BC Week In Review | Nov 17, 2014
Clinical News

RST-001 regulatory update

RetroSense said FDA granted Orphan Drug designation to intravitreal RST-001 to treat retinitis pigmentosa. The adeno-associated virus (AAV) vector encoding the gene for channelrhodopsin-2 (ChR2) is in preclinical testing to treat retinitis pigmentosa and wet...
BC Innovations | Apr 25, 2013
Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Mouse models for neurological disease controlled with cellular-scale optogenetic brain implants Mice with cellular-scale optogenetic devices implanted in the brain could be useful for developing...
BioCentury | Apr 15, 2013
Product Development

Gene therapy in sight

Gene therapy has been more or less off the radar for years, but last week's big series A round for GenSight Biologics Inc. reflects the investors' confidence that gene therapies for the eye can be...
BC Innovations | Mar 7, 2013

Big brain science

The Brain Activity Map, an academic consortium that aims to measure and model all the connections in living brains, has garnered mass media attention and comparisons to the Human Genome Project. However, unlike mapping the...
BioCentury | Aug 27, 2012
Emerging Company Profile

RetroSense: Seeing the light

RetroSense Therapeutics LLC is developing a gene therapy that is designed to restore vision in blind retinitis pigmentosa patients. The company is sidestepping the primary affected cells in the disease - photoreceptors - and instead is introducing...
BC Week In Review | Feb 20, 2012
Company News

RetroSense Therapeutics ophthalmic, gene/cell therapy news

RetroSense received a $250,000 grant from the Foundation Fighting Blindness to develop a gene therapy technology to ophthalmic indications. Last October, Wayne State University granted the company exclusive, worldwide rights to develop and commercialize the...
BioCentury | Jul 19, 2010
Emerging Company Profile

Eos Neuroscience: Lighting the way

When photoreceptor cells die, the retina is no longer sensitive to light even though retinal cells downstream in the phototransduction cascade remain intact. Eos Neuroscience Inc. is developing a gene therapy to make a specific...
Items per page:
1 - 10 of 12